PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events

被引:41
作者
Agell, Laia [1 ,2 ]
Hernandez, Silvia [3 ]
Salido, Marta [1 ,4 ]
de Muga, Silvia [1 ,2 ]
Juanpere, Nuria [1 ,2 ]
Arumi-Uria, Montserrat [1 ,5 ]
Menendez, Silvia [5 ]
Lorenzo, Marta [1 ]
Lorente, Jose A. [2 ,6 ]
Serrano, Sergio [1 ,2 ]
Lloreta, Josep [1 ]
机构
[1] Hosp Mar Parc Salut Mar, Dept Pathol, Barcelona, Spain
[2] Autonomous Univ Barcelona, Barcelona, Spain
[3] Univ Pompeu Fabra, Hosp Mar Parc Salut Mar, Dept Pathol, Dept Hlth & Expt Sci, Barcelona 08003, Spain
[4] Hosp Mar IMAS IMIM, Dept Pathol, Mol Cytogenet Lab, Barcelona, Spain
[5] IMIM, Canc Res Program, Barcelona, Spain
[6] Hosp Mar IMAS IMIM, Dept Urol, Barcelona, Spain
关键词
AKT1; FISH; KRAS; overexpression; PIK3CA; prostate; COLORECTAL-CANCER; FGFR3; MUTATIONS; ONCOGENIC PI3K; CARCINOMA; GENE; ADENOCARCINOMA; EXPRESSION; SURVIVAL; JAPANESE; SYSTEM;
D O I
10.1038/modpathol.2010.208
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The phosphatidylinositol 3-kinase (PI3K)-AKT and RAS-MAPK pathways are deregulated in a wide range of human cancers by gain or loss of function in several of their components. Our purpose has been to identify genetic alterations in members of these pathways in prostate cancer. A total of 102 prostate tumors, 79 from prostate cancer alone (group G1) and 23 from bladder and prostate cancer patients (G2), are the subject of this study. In 20 of these 23, the bladder tumors were also analyzed. PIK3CA, KRAS, BRAF and AKT1 mutations were analyzed by direct sequencing, and BRAF also by pyrosequencing. PIK3CA quantitative mRNA expression and fluorescence in situ hybridization (FISH) gains were tested in 25 and 32 prostate tumors from both groups (G1 and G2), respectively. Immunohistochemistry for pAKT was performed in 55 prostate tumors. Of 25 prostate tumors, 10 (40%) had PIK3CA mRNA overexpression that was statistically associated with Gleason score >= 7 (P=0.018). PIK3CA copy gain was detected in 9 of 32 (28%) prostate tumors. Of 20 bladder tumors, 3 (15%) displayed mutations in PIK3CA, KRAS and AKT1, the corresponding prostate tumors being wt. We also detected a previously not reported PIK3CA polymorphism (IVS9 + 91) in two prostate tumors. In all, 56% of prostate tumors overexpressed pAKT. There is a statistical association (P < 0.0001) of strong pAKT immunostaining with high Gleason score, and with PIK3CA alterations (mRNA overexpression and/or FISH gains). PIK3CA gene is deregulated by mRNA overexpression and DNA gain in 40 and 28% of prostate tumors, respectively. High-grade prostate tumors are associated with PIK3CA mRNA overexpression, but not with FISH status. PIK3CA, BRAF, KRAS and AKT1 mutations are very infrequent events in prostate tumors. However, PI3K signaling pathway is activated by PIK3CA FISH gain and/or mRNA overexpression, leading to an increased pAKT protein expression. Modern Pathology (2011) 24, 443-452; doi:10.1038/modpathol.2010.208; published online 26 November 2010
引用
收藏
页码:443 / 452
页数:10
相关论文
共 38 条
[1]   Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population [J].
Abubaker, Jehad ;
Jehan, Zeenath ;
Bavi, Prashant ;
Sultana, Mehar ;
Al-Harbi, Sayer ;
Ibrahim, Muna ;
Al-Nuaim, Abdulrahman ;
Ahmed, Mohammed ;
Amin, Tarek ;
Al-Fehaily, Maha ;
Al-Sanea, Osama ;
Al-Dayel, Fouad ;
Uddin, Shahab ;
Al-Kuraya, Khawla S. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02) :611-618
[2]   Oncogenic PI3K deregulates transcription and translation [J].
Bader, AG ;
Kang, SY ;
Zhao, L ;
Vogt, PK .
NATURE REVIEWS CANCER, 2005, 5 (12) :921-929
[3]   AKT1E17K in human solid tumours [J].
Bleeker, F. E. ;
Felicioni, L. ;
Buttitta, F. ;
Lamba, S. ;
Cardone, L. ;
Rodolfo, M. ;
Scarpa, A. ;
Leenstra, S. ;
Frattini, M. ;
Barbareschi, M. ;
Del Grammastro, M. ;
Sciarrotta, M. G. ;
Zanon, C. ;
Marchetti, A. ;
Bardelli, A. .
ONCOGENE, 2008, 27 (42) :5648-5650
[4]  
Blount LV, 1996, PROSTATE, V28, P44
[5]   An activating mutation in AKT1 in human prostate cancer [J].
Boormans, Joost L. ;
Hermans, Karin G. ;
van Leenders, Geert J. L. H. ;
Trapman, Jan ;
Verhagen, Paul C. M. S. .
INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (11) :2725-2726
[6]   Phosphoinositide 3-kinases in cell migration [J].
Cain, Robert J. ;
Ridley, Anne J. .
BIOLOGY OF THE CELL, 2009, 101 (01) :13-29
[7]   Recent changes in prostate cancer mortality in Spain. Trends analysis from 1991 to 2005 [J].
Cayuela, A. ;
Rodriguez-Dominguez, S. ;
Vigil Martin, E. ;
Barrero Candau, R. .
ACTAS UROLOGICAS ESPANOLAS, 2008, 32 (02) :184-189
[8]   Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma [J].
Chadha, Krishdeep S. ;
Khoury, Thaer ;
Yu, Jihnhee ;
Black, Jennifer D. ;
Gibbs, John F. ;
Kuvshinoff, Boris W. ;
Tan, Dongfeng ;
Brattain, Michael G. ;
Javle, Milind M. .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (07) :933-939
[9]   BRAF and KRAS mutations in prostatic adenocarcinoma [J].
Cho, Nam-Yun ;
Choi, Minhee ;
Kim, Baek-Hee ;
Cho, Yong-Mee ;
Moon, Kyung Chul ;
Kang, Gyeong Hoon .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (08) :1858-1862
[10]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627